Trial Profile
The effectiveness and safety of two von Willebrand factor/ Factor VIII concentrates, Wilate vs. Humate-P, in von Willebrand disease type III: on the way toward the cost-effectiveness study
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 28 Feb 2018
Price :
$35
*
At a glance
- Drugs Factor VIII/von Willebrand factor (Primary)
- Indications Haemophilia; Von Willebrand disease
- Focus Therapeutic Use
- Sponsors Pourateb
- 22 Feb 2018 Status changed from recruiting to completed.
- 10 Mar 2017 New trial record